Stockscreener 앱 받기
0.99
1.98%
-0.02
시간 외 거래:
1.03
0.04
+4.04%
전일 마감가:
$1.01
열려 있는:
$1.02
하루 거래량:
114.54K
Relative Volume:
5.08
시가총액:
$31.85M
수익:
-
순이익/손실:
-
주가수익비율:
-2.844
EPS:
-0.3481
순현금흐름:
-
1주 성능:
-1.98%
1개월 성능:
-11.61%
6개월 성능:
-20.17%
1년 성능:
-68.77%
1일 변동 폭
$0.9656
$1.03
1주일 범위
$0.9622
$1.06
52주 변동 폭
$0.85
$4.2185
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
명칭
Akari Therapeutics Plc Adr
전화
(646) 350-0702
주소
22 BOSTON WHARF ROAD, BOSTON
AKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.99 | 31.69M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Maxim Group | Buy |
| 2019-01-04 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | 업그레이드 | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 재확인 | Chardan Capital Markets | Sell |
| 2016-07-11 | 개시 | Chardan Capital Markets | Sell |
모두보기
Akari Therapeutics Plc Adr 주식(AKTX)의 최신 뉴스
Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Oncology Deal Veteran Mark Kubik Joins Akari Therapeutics to Accelerate ADC Pipeline Growth - Stock Titan
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India
Akari Therapeutics appoints new head of oncology business - Investing.com
Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics names new CEO to drive cancer drug innovation By Investing.com - Investing.com South Africa
Ibotta Inc (IBTA) Shares Soar Above 1-Year High - The News Heater
Akari Therapeutics Appoints New CEO, Current CEO to Step Down By Investing.com - Investing.com South Africa
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com India
Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas
Citi reveló que Ecopetrol ha publicado la guía de sus resultados para el cuarto trimestre de 2024 - Yahoo Finanzas
Major ADC Developer Akari Opens Direct Channel to Investors Through Webull Platform - StockTitan
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status - StockTitan
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas
¿Qué empresas del Ibex 35 también cotizan fuera de España? - Yahoo Finanzas
Bancolombia inicia programa para aumentar la liquidez de sus acciones - Yahoo Finanzas
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology - StockTitan
Trending UK-Based Penny Stock Picks 2024 - timothysykes.com
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
Las 100 empresas latinoamericanas que se han lanzado a conquistar Wall Street - Yahoo Finanzas
Tras filtración de datos, las acciones de Globant se hundieron 10% - Yahoo Finanzas
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
‘Flying Whale’ Blimp That Never Lands Joins Global Airship Race - Bloomberg.com
Akari Therapeutics PLC Stock Price Today | NASDAQ: AKTX Live - Investing.com
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
Akari Therapeutics Plc Adr (AKTX) 재무 분석
Akari Therapeutics Plc Adr (AKTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):